SNPX - Synaptogenix Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 7.85 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -0.83 StockBond Score: -4.23 Company Description Synaptogenix Inc operates as a biopharmaceutical company with product candidates in preclinical and clinical development It focuses on developing a product platform based upon a drug candidate called Bryostatin1 for the treatment of Alzheimers disease The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions such as fragile X syndrome multiple sclerosis and Niemannpick type C disease Synaptogenix Inc has licensing agreements with Stanford University Icahn School of Medicine at Mount Sinai and The Board of Trustees of the Leland Stanford Junior University The company was incorporated in 2012 and is headquartered in New York New York